Nasdaq 100 Stocks SEC Filings — May 20, 2026
The May 20, 2026 batch of 23 NASDAQ-100 filings reveals a sharply bifurcated market: mega-cap semiconductor leaders NVIDIA and Analog Devices post explosive growth (85% and 37% YoY revenue gains), while micro-cap clinical-stage and pre-revenue companies (Immunovant, Aditxt, Loan AI, Mosaic) show accelerating cash burns, widening losses, and deteriorating balance sheets. Period-over-period comparisons confirm an AI-driven investment cycle is compressing margins at scale—NVIDIA's R&D spend surged 58.5% YoY, Intuit's R&D rose 18.8%—despite strong top-line growth. Capital allocation trends diverge sharply: NVIDIA announced an $80B buyback and 25x dividend hike, and Starbucks retired $1.32B in debt, contrasting with cash-strapped biotechs drawing on dilutive equity offerings (Immunovant raised $544M). Insider activity shows no direct selling signals in this batch, but shareholder dissent at Iridium (13.2% against say-on-pay) and ADI's $29M severance program hint at governance and restructuring risks. The portfolio-level takeaway is a 'growth-at-a-cost' regime favoring dominant AI beneficiaries, while speculative names face a liquidity crunch.